GLP-1 medications slow gastric emptying, keeping stomach contentsincluding gastric acidin the digestive system longer
TRIUMPH-1, the first Phase 3 efficacy readout, was reported on 21 May 2026
Regulatory Status
When to contact your GP or diabetes team : Persistent vomiting preventing fluid intake Severe abdominal pain, especially if radiating to the back (possible pancreatitis) Right upper abdominal pain, fever or jaundice (possible gallbladder problems) Signs of dehydration (dark urine, dizziness, reduced urination) Unexplained hypoglycaemia if on combination therapy New or worsening visual symptoms (especially if you have diabetic retinopathy) Allergic reactions (rash, swelling, breathing difficulties) Most patients tolerate GLP-1 medications well once past the initial adjustment period
You can explore our approach to weight management at Check Your Eligibility If you want to learn whether GLP-1 treatment is appropriate for your health needs and receive personalized guidance on nutrition and exercise during treatment, you can start by completing Mochis eligibility questionnaire
Although Wegovy has shown promising weight-loss results in clinical trials, its important to note that this medication is currently not intended for cosmetic purposes
